Beyond Folic Acid: Restoring Sulfur Metabolism to Combat Hyperhomocysteinemia
A comprehensive review reveals how transsulfuration pathway products and H₂S-donors may offer new therapeutic avenues for hyperhomocysteinemia.
Summary
Hyperhomocysteinemia (HHcy) is a major cardiometabolic risk factor linked to disruptions in the transsulfuration pathway, which normally converts homocysteine into protective compounds like cysteine, taurine, glutathione, and hydrogen sulfide (H₂S). While folic acid supplementation is the conventional approach to lower homocysteine, this review argues that downstream transsulfuration products—taurine, N-acetylcysteine, serine, and H₂S-donors—may provide additional, complementary benefits. Preclinical and clinical evidence shows these compounds can reduce oxidative stress, inflammation, and endothelial dysfunction associated with HHcy, independent of directly lowering homocysteine levels. The authors propose that multi-target strategies addressing the full transsulfuration axis could better prevent the multiorgan complications of HHcy than folate therapy alone.
Detailed Summary
Hyperhomocysteinemia (HHcy)—defined as pathologically elevated plasma homocysteine (Hcy)—is a well-established risk factor for atherosclerosis, hypertension, stroke, heart failure, and metabolic diseases including type 2 diabetes. It arises when the transsulfuration pathway is disrupted: instead of Hcy being efficiently converted into cysteine and protective downstream metabolites, it accumulates and drives oxidative stress, endothelial dysfunction, epigenetic dysregulation (via altered SAM/SAH ratios and global DNA hypomethylation), and inflammation. This narrative review from the University of Pisa synthesizes preclinical and clinical literature to map both the mechanisms of HHcy-associated damage and emerging therapeutic strategies.
The transsulfuration pathway converts Hcy—derived from dietary methionine via the methionine cycle—into cystathionine (via CBS), then cysteine (via CSE), and onward to taurine, reduced glutathione (GSH), pyruvate, serine, and the gasotransmitter hydrogen sulfide (H₂S). The folate cycle closely regulates methionine remethylation; deficiencies in folate, vitamin B12, or enzymes such as MTHFR and CBS are common causes of HHcy. Remarkably, centenarians show upregulated transsulfuration activity with higher plasma cysteine and cystathionine levels compared to non-centenarians, underscoring the pathway's longevity relevance.
Folic acid, the standard treatment, reduces Hcy by boosting remethylation, indirectly restoring transsulfuration balance and raising total antioxidant capacity and serum GSH. However, its benefits on cardiovascular endpoints in clinical trials have been inconsistent, motivating the search for complementary strategies. The review examines downstream transsulfuration products: taurine exerts direct antioxidant and anti-inflammatory effects, stabilizes mitochondrial function, inhibits ROS-generating enzymes (XO, NOX), and activates Nrf2-mediated antioxidant gene expression. N-acetylcysteine (NAC), a GSH precursor and direct ROS scavenger, has demonstrated efficacy in reducing endothelial oxidative stress in HHcy models. Serine, as a substrate for the folate and methionine cycles, may help re-route Hcy metabolism. These agents appear to offer benefits beyond simple Hcy lowering.
Particularly compelling is the evidence around H₂S. Reduced H₂S levels have been documented in CBS⁺/⁻ mice, Hcy-treated rats, and in the retina of diabetic mice with HHcy. Pharmacological H₂S-donors (including GYY4137, NaHS, and natural polysulfide-containing compounds) have shown anti-oxidant, anti-inflammatory, vasorelaxant, and cardioprotective effects in HHcy cell culture and animal models, acting through S-sulfhydration of target proteins and activation of KATP channels and Nrf2 pathways. The existence of an 'extracellular transsulfuration system'—where CBS and CSE secreted by endothelial cells and hepatocytes generate H₂S from extracellular Hcy—adds further mechanistic plausibility to H₂S-based interventions.
The authors conclude that a multi-pronged strategy combining folate cycle support with supplementation of transsulfuration downstream products (taurine, NAC/GSH precursors) and H₂S-donors represents a promising and underexplored therapeutic framework. This approach could address not only elevated Hcy per se but also the downstream deficits in antioxidant and cytoprotective mediators that drive HHcy-associated multiorgan damage.
Key Findings
- Centenarians have significantly higher plasma cysteine and cystathionine, linking active transsulfuration to exceptional longevity.
- HHcy reduces H₂S biosynthesis across multiple models; H₂S-donors reverse associated oxidative stress and endothelial dysfunction.
- Taurine and NAC provide antioxidant and anti-inflammatory effects in HHcy beyond simply lowering homocysteine levels.
- HHcy disrupts SAM/SAH ratio, causing global DNA hypomethylation and epigenetic dysregulation of CBS and CSE genes.
- An extracellular CBS/CSE-based transsulfuration system in endothelial cells produces H₂S to protect vessels from Hcy toxicity.
Methodology
This is a comprehensive narrative review synthesizing preclinical (cell culture and animal model) and clinical studies on transsulfuration pathway dysfunction, HHcy, and candidate therapeutic agents. No original experimental data were generated; evidence is drawn from published literature across multiple model systems (CBS⁺/⁻ mice, diet-induced HHcy rats, ApoE⁻/⁻ mice, human endothelial cell cultures) and clinical cohort data.
Study Limitations
As a narrative review, it does not apply systematic review or meta-analytic methods, potentially introducing selection bias. The majority of mechanistic evidence is from animal and cell models; large randomized controlled trials of taurine, NAC, or H₂S-donors specifically for HHcy-associated cardiovascular endpoints are lacking. Causal directionality between transsulfuration pathway disruption and disease outcomes remains incompletely established in humans.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.